Table 3 Outcomes (stratified by inflammatory arthritis diagnosis)

N

132,672

106,098

21,871

6,643

Any Shingrix dose, n (%)

28,690 (21.6)

23,482 (22.1)

4,498 (20.6)

1,052 (15.8)

Any second Shingrix dose

21,012 (73.2)

17,265 (73.5)

3,252 (72.3)

743 (70.6)

 Second Shingrix dose 2–6 months after first dose

17,598 (83.8)

14,443 (83.7)

2,751 (84.6)

613 (82.5)

 Second Shingrix dose 2–9 months after first dose

19,226 (91.5)

15,781 (91.4)

2,998 (92.2)

675 (90.8)

 Second Shingrix dose 2–12 months after first dose

19,757 (94.0)

16,219 (93.9)

3,071 (94.4)

699 (94.1)

 ≥ 180 days’ enrollment after Shingrix vaccination, n (%)

24,475 (85.3)

20,090 (85.6)

3,796 (84.3)

885 (84.1)

Herpes zoster, n (%)

4,342 (3.3)

3,684 (3.5)

559 (2.6)

140 (2.1)

 IR per 1,000 PY (95% CI)

13.64 (13.23, 14.04)

14.27 (13.81, 14.73)

11.13 (10.21, 12.05)

9.88 (8.24, 11.51)

Myocardial infarction, n (%)

3,361 (2.5)

2,926 (2.8)

400 (1.8)

63 (0.9)

 IR per 1,000 PY (95% CI)

10.43 (10.08, 10.78)

11.20 (10.79, 11.60)

7.88 (7.11, 8.66)

4.39 (3.31, 5.48)

Stroke, n (%)

2,979 (2.2)

2,617 (2.5)

324 (1.5)

50 (0.8)

 IR per 1,000 PY (95% CI)

9.23 (8.90, 9.56)

10.00 (9.62, 10.39)

6.37 (4.58, 7.07)

3.48 (2.51, 4.44)

MACE, n (%)

6,227 (4.7)

5,429 (5.1)

720 (3.3)

119 (1.8)

 IR per 1,000 PY (95% CI)

19.56 (19.08, 20.05)

21.05 (20.49, 21.61)

14.32 (13.27, 15.36)

8.34 (6.84, 9.84)

VTE, n (%)

1,975 (1.5)

1,754 (1.7)

189 (0.9)

47 (0.7)

 IR per 1,000 PY (95% CI)

6.10 (5.83, 6.37)

6.68 (6.36, 6.99)

3.70 (3.18, 4.23)

3.27 (2.33, 4.20)